MV-s-NAP

AXP000114.1 · Oncolytic virus

Platform
measles virus (Edmonston-NSe vaccine lineage)
Originator
Mayo Clinic
Sponsor
Mayo Clinic

Names

NameTypeSource
MV-s-NAPpreferred name, codecurator, ncit
MV Encoding NAPsynonymncit

Virus

Role
Oncolytic
Family
Paramyxoviridae
Virus
measles morbillivirus (NCBI Taxonomy 11234)
Strain
Edmonston-NSe vaccine lineage
Replication
replicating
Modifications
secreted H. pylori neutrophil-activating protein cassette inserted
Transgenes
H. pylori NAP
Route
intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C173889

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT04521764A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast CancerRecruitingPhase 12020-09-232027-08-1554Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Carcinoma; Metastatic Breast Adenocarcinoma; Recurrent Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 36092362Preclinical safety assessment of MV-s-NAP, a novel oncolytic measles virus strain armed with an H . pylori immunostimulatory bacterial transgene.Molecular therapy. Methods & clinical development2022cited by trial NCT04521764

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41542034Repurposing the SSRI paroxetine increases lymphocyte mobilization and improves the efficacy of measles virus-based immunovirotherapy.Molecular therapy. Oncology2026name in abstract: MV-s-NAP
PMID 41235176Oncolytic measles virotherapy encoding the neutrophil-activating protein is effective in synovial sarcoma.Molecular therapy. Oncology2025name in abstract: MV-s-NAP
PMID 34196308Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy.The Journal of clinical investigation2021name in abstract: MV-s-NAP
PMID 22334023Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus.Molecular therapy : the journal of the American Society of Gene Therapy2012name in abstract: MV-s-NAP
PMID 21182995Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophil-activating protein.Vaccine2011name in abstract: MV-s-NAP

NIH grants

ProjectTitleOrganisationPIYearsLinked by
R01CA258239Novel multipronged Immunovirotherapy Approach for GBM TreatmentMAYO CLINIC ROCHESTERGALANIS, EVANTHIA2021–2025name in abstract: MV-s-NAP
P50CA116201Project 3: Measles virus based immunovirotherapy in the treatment of metastatic breast cancerMAYO CLINIC ROCHESTERGALANIS, EVANTHIA2016–2021name in abstract: MV-s-NAP

Notes

Edmonston-lineage measles virus encoding secreted Helicobacter pylori neutrophil-activating protein (NAP). Transgene is bacterial, so not an HGNC symbol.

How to cite

MV-s-NAP (AXP000114.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000114.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.